PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Heldner, A. ; Alessandrini, F. ; Russkamp, D. ; Heine, S. ; Schnautz, B. ; Chaker, A. ; Mwange, J.* ; Carreno Velazquez, T.L.* ; Heath, M.D.* ; Skinner, M.A.* ; Kramer, M.F.* ; Zissler, U.M. ; Schmidt-Weber, C.B. ; Blank, S.

Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy.

Allergy, DOI: 10.1111/all.15012 (2021)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Native allergen extracts or chemically modified allergoids are routinely used to induce allergen tolerance in allergen-specific immunotherapy (AIT), although mechanistic side-by-side studies are rare. It is paramount to balance optimal dose and allergenicity to achieve efficacy warranting safety. AIT safety and efficacy could be addressed by allergen dose reduction and/or use of allergoids and immunostimulatory adjuvants, respectively. In this study, immunological effects of experimental house dust mite (HDM) AIT were investigated applying high-dose HDM extract and low-dose HDM allergoids with and without the adjuvants microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL) in a murine model of HDM allergy. METHODS: Cellular, humoral, and clinical effects of the different AIT strategies were assessed applying a new experimental AIT model of murine allergic asthma based on physiological, adjuvant-free intranasal sensitization followed by subcutaneous AIT. RESULTS: While low-dose allergoid and high-dose extract AIT demonstrated comparable potency to suppress allergic airway inflammation and Th2-type cytokine secretion of lung-resident lymphocytes and draining lymph node cells, low-dose allergoid AIT was less effective in inducing a potentially protective IgG1 response. Combining low-dose allergoid AIT with MCT or MCT and dose-adjusted MPL promoted Th1-inducing mechanisms and robust B-cell activation counterbalancing the allergic Th2 immune response. CONCLUSION: Low allergen doses induce cellular and humoral mechanisms counteracting Th2-driven inflammation by using allergoids and dose-adjusted adjuvants. In light of safety and efficacy improvement, future therapeutic approaches may use low-dose allergoid strategies to drive cellular tolerance and adjuvants to modulate humoral responses.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
13.146
0.000
3
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Adjuvant ; Allergen Extract ; Allergen-specific Immunotherapy ; Allergoid ; House Dust Mite Allergy; Monophosphoryl-lipid-a; T-cell Responses; Subcutaneous Immunotherapy; Mpl(r); Tolerance; Vaccines; Antibody; Tyrosine; Model; Immunogenicity
Language english
Publication Year 2021
HGF-reported in Year 2021
ISSN (print) / ISBN 0105-4538
e-ISSN 1398-9995
Journal Allergy
Publisher Wiley
Publishing Place 111 River St, Hoboken 07030-5774, Nj Usa
Reviewing status Peer reviewed
Institute(s) Institute for Allergy Research (IAF)
POF-Topic(s) 30202 - Environmental Health
Research field(s) Allergy
PSP Element(s) G-505400-001
Grants Allergy Therapeutics plc.
Helmholtz-Gemeinschaft
DOI 10.1111/all.15012
WOS ID WOS:000678730900001
Scopus ID 85111436828
PubMed ID 34287971
Erfassungsdatum 2021-08-06
[➜Report correction]